Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29570815 | 1.00 | KIF11 (0.36) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL24326328 | 0.83 | PNMT (0.44) | KIF11ALDH1A1LMNA | |
| SCHEMBL3202387 | 0.79 | KIF11 (0.36) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL3202257 | 0.79 | KIF11 (0.38) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL25591834 | 0.77 | HTR2C (0.39) | KIF11ALDH1A1HSD17B10 | |
| SCHEMBL26795661 | 0.77 | ALDH1A1 (0.36) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL26795660 | 0.74 | CYP1A2 (0.38) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL30739381 | 0.73 | CHRNB2 (0.34) | ALDH1A1ALOX15 | |
| SCHEMBL30228097 | 0.73 | KDM1A (0.35) | HSD17B10 | |
| SCHEMBL1875659 | 0.73 | KDM1A (0.35) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-1817837-B | Carbonyl compound and method for preparing the same | SUMITOMO CHEMICAL CO | 2010-06-16 | — | — | CN | disclosed |
| US-7732643-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7671226-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | HANAOKA HIDENORI | 2010-02-25 | — | — | US | disclosed |
| EP-1426379-B1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | SUMITOMO CHEMICAL CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | HANAOKA HIDENORI | 2009-02-26 | — | — | US | disclosed |
| US-7439379-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| CN-100357303-C | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer using the same | SUMITOMO CHEMICAL CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| CN-1817837-A | Substituted cyclopentadiene and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2006-08-16 | — | — | CN | disclosed |
| CN-1578783-A | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer using the same | SUMITOMO CHEMICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
| US-20040242410-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1426379-A1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | C1R, C1S, AP1M1 | KIF11 1584/4885ALDH1A1 1229/4885HPGD 3475/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KIF11 4517/4885ALDH1A1 4077/4885HPGD 1773/4885 |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | C1R, C1S, AP1M1 | KIF11 1584/4885ALDH1A1 1229/4885HPGD 3475/4885 |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KIF11 4468/4885ALDH1A1 3967/4885HPGD 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.